Analysis of a large national cancer database similarly demonstrated NSCLC to have a high messenger RNA expression of CEACAM5 compared with normal and in line with pancreatic, gastric, and esophageal cancers for which glycoprotein is an established clinical diagnostic and prognostic marker (eFigure 3 in Supplement 2).16,29 In addition, although the sample size was small, higher CEACAM5 expression was noted in higher-stage disease. This evidence concerns the gene CEACAM5 and cancer.